Executive summary: British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease

Elizabeth J Price; Stuart Benjamin; Michele Bombardieri; Simon Bowman; Sara Carty; Coziana Ciurtin; Bridget Crampton; Annabel Dawson; Benjamin A Fisher; Ian Giles; Peter Glennon; Monica Gupta; Katie L Hackett; Genevieve Larkin; Wan-Fai Ng; Athimalaipet V Ramanan; Saad Rassam; Saaeha Rauz; Guy Smith; Nurhan Sutcliffe; Anwar Tappuni; Stephen B Walsh

doi:10.1093/rheumatology/keae218

Executive summary: British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease

Elizabeth J Price^*
, Stuart Benjamin
, Michele Bombardieri
, Simon Bowman
, Sara Carty
, Coziana Ciurtin
, Bridget Crampton
, Annabel Dawson
, Benjamin A Fisher
, Ian Giles
, Peter Glennon
, Monica Gupta
, Katie L Hackett
, Genevieve Larkin
, Wan-Fai Ng
, Athimalaipet V Ramanan
, Saad Rassam
, Saaeha Rauz
, Guy Smith
, Nurhan Sutcliffe

Anwar Tappuni, Stephen B Walsh

^*Corresponding author for this work

Research output: Contribution to journal › Article (Academic Journal) › peer-review

3 Citations (Scopus)

Abstract

Sjögren disease (SD) is a chronic, auto-immune disease of unknown aetiology with significant impact on quality of life (QoL) [1]. Although dryness (sicca) of the eyes and mouth are the classically described features, dryness of other mucosal surfaces and systemic manifestations are common. The key management aim should be to empower the individuals to manage their condition; conserving, replacing and stimulating secretions; preventing damage and suppressing systemic disease activity.

This guideline builds on, and widens the recommendations developed for the first guideline published in 2017 [2]. We have included advice on the management of children and adolescents where appropriate to provide a comprehensive guideline for UK-based rheumatology teams.

Original language	English
Pages (from-to)	1-13
Number of pages	13
Journal	Rheumatology
Early online date	24 May 2024
DOIs	https://doi.org/10.1093/rheumatology/keae218
Publication status	E-pub ahead of print - 24 May 2024

Access to Document

10.1093/rheumatology/keae218Licence: CC BY

Handle.net

Persistent link

Cite this

Price, E. J., Benjamin, S., Bombardieri, M., Bowman, S., Carty, S., Ciurtin, C., Crampton, B., Dawson, A., Fisher, B. A., Giles, I., Glennon, P., Gupta, M., Hackett, K. L., Larkin, G., Ng, W.-F., Ramanan, A. V., Rassam, S., Rauz, S., Smith, G., ... Walsh, S. B. (2024). Executive summary: British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease. Rheumatology, 1-13. Advance online publication. https://doi.org/10.1093/rheumatology/keae218

@article{63c24469cdad47b8aab9d5b0a3401b88,

title = "Executive summary: British Society for Rheumatology guideline on management of adult and juvenile onset Sj{\"o}gren disease",

abstract = "Sj{\"o}gren disease (SD) is a chronic, auto-immune disease of unknown aetiology with significant impact on quality of life (QoL) [1]. Although dryness (sicca) of the eyes and mouth are the classically described features, dryness of other mucosal surfaces and systemic manifestations are common. The key management aim should be to empower the individuals to manage their condition; conserving, replacing and stimulating secretions; preventing damage and suppressing systemic disease activity. This guideline builds on, and widens the recommendations developed for the first guideline published in 2017 [2]. We have included advice on the management of children and adolescents where appropriate to provide a comprehensive guideline for UK-based rheumatology teams.",

author = "Price, \{Elizabeth J\} and Stuart Benjamin and Michele Bombardieri and Simon Bowman and Sara Carty and Coziana Ciurtin and Bridget Crampton and Annabel Dawson and Fisher, \{Benjamin A\} and Ian Giles and Peter Glennon and Monica Gupta and Hackett, \{Katie L\} and Genevieve Larkin and Wan-Fai Ng and Ramanan, \{Athimalaipet V\} and Saad Rassam and Saaeha Rauz and Guy Smith and Nurhan Sutcliffe and Anwar Tappuni and Walsh, \{Stephen B\}",

year = "2024",

month = may,

day = "24",

doi = "10.1093/rheumatology/keae218",

language = "English",

pages = "1--13",

journal = "Rheumatology",

issn = "1462-0324",

publisher = "Oxford University Press",

}

Price, EJ, Benjamin, S, Bombardieri, M, Bowman, S, Carty, S, Ciurtin, C, Crampton, B, Dawson, A, Fisher, BA, Giles, I, Glennon, P, Gupta, M, Hackett, KL, Larkin, G, Ng, W-F, Ramanan, AV, Rassam, S, Rauz, S, Smith, G, Sutcliffe, N, Tappuni, A & Walsh, SB 2024, 'Executive summary: British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease', Rheumatology, pp. 1-13. https://doi.org/10.1093/rheumatology/keae218

TY - JOUR

T1 - Executive summary

T2 - British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease

AU - Price, Elizabeth J

AU - Benjamin, Stuart

AU - Bombardieri, Michele

AU - Bowman, Simon

AU - Carty, Sara

AU - Ciurtin, Coziana

AU - Crampton, Bridget

AU - Dawson, Annabel

AU - Fisher, Benjamin A

AU - Giles, Ian

AU - Glennon, Peter

AU - Gupta, Monica

AU - Hackett, Katie L

AU - Larkin, Genevieve

AU - Ng, Wan-Fai

AU - Ramanan, Athimalaipet V

AU - Rassam, Saad

AU - Rauz, Saaeha

AU - Smith, Guy

AU - Sutcliffe, Nurhan

AU - Tappuni, Anwar

AU - Walsh, Stephen B

PY - 2024/5/24

Y1 - 2024/5/24

N2 - Sjögren disease (SD) is a chronic, auto-immune disease of unknown aetiology with significant impact on quality of life (QoL) [1]. Although dryness (sicca) of the eyes and mouth are the classically described features, dryness of other mucosal surfaces and systemic manifestations are common. The key management aim should be to empower the individuals to manage their condition; conserving, replacing and stimulating secretions; preventing damage and suppressing systemic disease activity. This guideline builds on, and widens the recommendations developed for the first guideline published in 2017 [2]. We have included advice on the management of children and adolescents where appropriate to provide a comprehensive guideline for UK-based rheumatology teams.

AB - Sjögren disease (SD) is a chronic, auto-immune disease of unknown aetiology with significant impact on quality of life (QoL) [1]. Although dryness (sicca) of the eyes and mouth are the classically described features, dryness of other mucosal surfaces and systemic manifestations are common. The key management aim should be to empower the individuals to manage their condition; conserving, replacing and stimulating secretions; preventing damage and suppressing systemic disease activity. This guideline builds on, and widens the recommendations developed for the first guideline published in 2017 [2]. We have included advice on the management of children and adolescents where appropriate to provide a comprehensive guideline for UK-based rheumatology teams.

U2 - 10.1093/rheumatology/keae218

DO - 10.1093/rheumatology/keae218

M3 - Article (Academic Journal)

C2 - 38785300

SN - 1462-0324

SP - 1

EP - 13

JO - Rheumatology

JF - Rheumatology

ER -

Executive summary: British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease

Abstract

Access to Document

Handle.net

Fingerprint

Cite this